Clinical trial
Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized…
NCT00122863 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00122863 |
|---|---|
| Title | Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder |
| Official title | Duloxetine 60 to 120 mg Once Daily Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Boehringer Ingelheim Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anxiety Disorders |
| Intervention type | Drug |
| Interventions | Duloxetine Hydrochloride, placebo |
| Enrollment | 380 |
| Start date | Jan 1, 2005 |
| Completion | Mar 1, 2007 |
| First posted | Jul 22, 2005 |
| Last update posted | Aug 31, 2007 |
| Countries | Austria, France, Germany, Netherlands, Portugal, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: